ChromaDex Corporation Reports Third Quarter 2018 Financial Results

hird Quarter 2018 Highlights vs. Third Quarter 2017 Net sales up 33%, fueled by growth of TRU NIAGEN®, which increased by 97%; TRU NIAGEN...

ChromaDex: Is Elysium About To Get In Trouble?

ChromaDex (CDX) is known by investors as the manufacturer of Nicotinamide Riboside, more commonly referred to as NR, an anti-aging nutraceutical. They are also...

October Review, Earnings Preview

October has a reputation for being a bad month to own stocks. For the current generation of investors, this reputation was earned primarily from...

CDXC Takes A Hit On Frost & Honig’s SEC Troubles

Shares in Chromadex were hit hard today, losing over 9% and closing at levels not seen since early July. This action in the stock...

ChromaDex Corporation Reports Second Quarter 2018 Financial Results

IRVINE, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN®...

ChromaDex and Watsons Expand TRU NIAGEN® Retail Partnership Through 2021

IRVINE, Calif., Aug. 07, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age with its flagship ingredient NIAGEN® and...

Fourth Published Clinical Trial Confirms Long-Term Safety of NIAGEN® Supplementation at High Doses and...

IRVINE, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corp. (NASDAQ:CDXC), an integrated, science-based, nutraceutical company devoted to improving the way people age, announced today that results from...

TRU NIAGEN® to be featured at the American Society for Nutrition’s Annual Meeting

Tailwinds' Take: CDXC stock has been weak with a combination of lack of news and forecasted sales not picking up until Q3 weighing on...

With Earnings Season Over, Which Stocks Surprised Us?

Quarterly earnings season is the four times each year in which companies give investors an inside look as to what's going on. They not...

ChromaDex Appoints Nobel Laureate, Professor Sir John Walker, to the Scientific Advisory Board

Tailwinds' Take: expect a lot more work to be done around Alzheimer's with the help of this leading researcher.  RVINE, Calif., May 14, 2018 (GLOBE NEWSWIRE) -- ChromaDex...

Recapping This Week’s Earnings, and How Tailwinds Is Playing Each Stock

Many companies in the Tailwinds (TW) coverage universe reported earnings this last week. Here we discuss each of their results (alphabetically), along with a...

ChromaDex Corporation Reports First Quarter 2018 Financial Results

Tailwinds' Take: this is not a shocking number, but would have liked them to guide to growth resuming sooner. We had trimmed after the...

ChromaDex Appoints Frank Jaksch As Executive Chairman, Rob Fried as Chief Executive Officer and...

Tailwinds' Take: Not a surprise that Jaksch moves out of the CEO role as this morphs into a consumer company. Fried is an experienced...

ChromaDex Meeting Notes

I had the opportunity to stop by the offices of ChromaDex (CDXC) last week in LA. It was a beautiful day in LA and...

New Published Clinical Trial Confirms NIAGEN® Supplementation Raised Nicotinamide Adenine Dinucleotide (NAD) Levels and...

Tailwinds' Take: this study reached easily reached the primary endpoint of demonstrating that Niagen increases NAD+ levels. Importantly, the cardiovascular data shows that it...

Chromadex is Data Dependent…Boulder Study Coming Soon

Shares of Chromadex are not cheap. When you look at this company relative to sales, the $200+ million market cap sticks out like a...

ChromaDex Corporation Reports 2017 Financial Results

IRVINE, Calif., March 08, 2018 (GLOBE NEWSWIRE) -- ChromaDex Corporation (NASDAQ:CDXC), a science-based, integrated nutraceutical company devoted to improving the way people age, announced today fourth quarter and...

Why I Tell My Friends to Take Niagen

Thanks to a recent article in Time Magazine, Nicotinamide Riboside and NAD replenishment are getting a lot of attention. Because I have been taking NR...

Two Additional Collaborative Human Studies on NIAGEN® with the University of Cambridge and the...

Tailwinds' Take: with nearly 140 trials underway involving Niagen, CDXC has more than its share of catalysts coming in the near future. These two...

CDXC Seller Revealed in Filings

One of our top picks, Chromadex shares have been under pressure over the last few months. The shares hit a high of around $7...